Exome Asset Management LLC 13F: Quarter-over-Quarter Portfolio Changes
Exome Asset Management LLC reported a disclosed portfolio value of approximately $169.9 million in its latest SEC Form 13F-HR filing for Q1 2026, down 16.0% quarter on quarter. Over the quarter, the fund initiated 14 new positions, bought more shares in 4 holdings, trimmed 23 holdings, and exited 22 positions.
Exome Asset Management LLC's top buy was a new stake in Insmed INC (INSM) , equal to 2.6% of the disclosed portfolio. Its top sell was Wave Life Sciences LTD. (WVE) . The fund exited the position completely after it had accounted for 3.5% of the previous portfolio.
New PositionsQ1 2026
Securities disclosed for the first time in Q1 2026 that were not present in the prior 13F-HR filing.
| Company | Ticker | Initial Portfolio Weight | History |
|---|---|---|---|
| INSMED INC | INSM | 2.6% | Holders → |
| MOONLAKE IMMUNOTHERAPEUTICS | MLTX | 2.4% | Holders → |
| RHYTHM PHARMACEUTICALS, INC. | RYTM | 2.1% | Holders → |
| BOSTON SCIENTIFIC CORP | BSX | 1.8% | Holders → |
| ALKERMES PLC | ALKS | 1.7% | Holders → |
| MONTE ROSA THERAPEUTICS INC | GLUE | 1.7% | Holders → |
| CRESCENT BIOPHARMA INC. | CBIO | 1.7% | Holders → |
| RELAY THERAPEUTICS INC | RLAY | 1.6% | Holders → |
| MAZE THERAPEUTICS INC | MAZE | 1.6% | Holders → |
| AVALO THERAPEUTICS INC | AVTX | 1.4% | Holders → |
| SOLENO THERAPEUTICS INC | SLNO | 1.2% | Holders → |
| ZENAS BIOPHARMA INC | ZBIO | 0.9% | Holders → |
| 4D MOLECULAR THERAPEUTICS IN | FDMT | 0.7% | Holders → |
| LIPOCINE INC NEW | LPCN | 0.3% | Holders → |
Top BuysQ1 2026
The fund's top buys among existing positions in Q1 2026. Ranked by portfolio-weight impact, with the percentage of additional shares shown separately.
| Company | Ticker | Portfolio Weight Change | More Shares | History |
|---|---|---|---|---|
| UNITEDHEALTH GROUP | UNH | +1.1% | +120.4% | Holders → |
| CORBUS PHARMACEUTICALS HLDGS | CRBP | +0.7% | +67.8% | Holders → |
| VERASTEM | VSTM | +0.5% | +58.5% | Holders → |
| NOVABRIDGE BIOSCIENCES | NBP | +-0.1% | +15.5% | Holders → |
Top SellsQ1 2026
Showing the top 10 sells among 23 existing positions where the fund sold shares in Q1 2026. Ranked by portfolio-weight impact. Full exits are listed separately.
| Company | Ticker | Portfolio Weight Change | Shares Sold | History |
|---|---|---|---|---|
| LIQUIDIA CORPORATION | LQDA | -0.5% | 49.8% | Holders → |
| APELLIS PHARMACEUTICALS INC | APLS | 0.3% | 37.0% | Holders → |
| GLAUKOS CORP | GKOS | -0.4% | 33.7% | Holders → |
| ADAGENE INC | ADAG | 0.7% | 30.5% | Holders → |
| CYTOMX THERAPEUTICS, INC. | CTMX | -0.1% | 30.0% | Holders → |
| NEXTCURE INC | NXTC | -0.4% | 30.0% | Holders → |
| PENUMBRA INC | PEN | -0.2% | 30.0% | Holders → |
| PRAXIS PRECISION MEDICINES I | PRAX | 0.2% | 21.8% | History → |
| PALISADE BIO INC | PALI | -0.3% | 20.9% | Holders → |
| CYTOKINETICS INC | CYTK | 0.1% | 16.9% | History → |
Full ExitsQ1 2026
Positions present in the prior 13F-HR filing that no longer appear in Q1 2026.
| Company | Ticker | Last-Reported Portfolio Weight |
|---|---|---|
| WAVE LIFE SCIENCES LTD. | WVE | 3.5% |
| ASTRAZENECA PLC | AZN | 2.6% |
| JAZZ PHARMACEUTICALS PLC | JAZZ | 2.2% |
| IMMUNOVANT INC | IMVT | 2.0% |
| UNIVERSAL HLTH SVCS INC | UHS | 1.9% |
| DISC MEDICINE INC | IRON | 1.8% |
| CELCUITY INC | CELC | 1.7% |
| TRAVERE THERAPEUTICS INC | TVTX | 1.7% |
| DEXCOM INC | DXCM | 1.6% |
| IMMUNOCORE HLDGS PLC | IMCR | 1.3% |
| EDGEWISE THERAPEUTICS, INC. | EWTX | 1.2% |
| BELITE BIO INC | BLTE | 1.1% |
| WAYSTAR HLDG CORP | WAY | 1.1% |
| IRONWOOD PHARMACEUTICALS INC | IRWD | 1.1% |
| KARYOPHARM THERAPEUTICS INC | KPTI | 1.1% |
| UPSTREAM BIO INC | UPB | 0.9% |
| GOSSAMER BIO INC | GOSS | 0.7% |
| INHIBIKASE THERAPEUTICS INC | IKT | 0.6% |
| IQVIA HLDGS INC (IQV) | IQV | 0.6% |
| TENET HEALTHCARE CORP | THC | 0.6% |
| FULCRUM THERAPEUTICS INC | FULC | 0.5% |
| RAPT THERAPEUTICS INC | RAPT | 0.2% |
Net Portfolio Value ChangeQ1 2026
- $0.2BPrior quarter
- $0.2BCurrent quarter
- $-0.0BNet delta
- -16.0%% change
Methodology & FAQ
How Exome Asset Management LLC Quarterly Changes Are Computed
All deltas are sourced from sequential SEC Form 13F-HR filings for Exome Asset Management LLC: each row joins the most recent filing against the immediately preceding quarterly filing for the same fund. Share-count changes reflect reported trading activity, while portfolio weights can also move because of market price changes. Portfolio weights are normalized to exclude listed options for comparability. A complete description — including how confidential treatment filings are handled — is documented in the Methodology.
What stocks did Exome Asset Management LLC buy in Q1 2026?
In Q1 2026, Exome Asset Management LLC initiated 14 new positions (INSMED INC (INSM), MOONLAKE IMMUNOTHERAPEUTICS (MLTX), RHYTHM PHARMACEUTICALS, INC. (RYTM), BOSTON SCIENTIFIC CORP (BSX), ALKERMES PLC (ALKS), MONTE ROSA THERAPEUTICS INC (GLUE), CRESCENT BIOPHARMA INC. (CBIO), RELAY THERAPEUTICS INC (RLAY), MAZE THERAPEUTICS INC (MAZE), AVALO THERAPEUTICS INC (AVTX), SOLENO THERAPEUTICS INC (SLNO), ZENAS BIOPHARMA INC (ZBIO), 4D MOLECULAR THERAPEUTICS IN (FDMT), LIPOCINE INC NEW (LPCN)); bought more shares of UNITEDHEALTH GROUP (UNH), CORBUS PHARMACEUTICALS HLDGS (CRBP), VERASTEM (VSTM), NOVABRIDGE BIOSCIENCES (NBP).
What stocks did Exome Asset Management LLC sell in Q1 2026?
In Q1 2026, Exome Asset Management LLC fully sold 22 positions (WAVE LIFE SCIENCES LTD. (WVE), ASTRAZENECA PLC (AZN), JAZZ PHARMACEUTICALS PLC (JAZZ), IMMUNOVANT INC (IMVT), UNIVERSAL HLTH SVCS INC (UHS), DISC MEDICINE INC (IRON), CELCUITY INC (CELC), TRAVERE THERAPEUTICS INC (TVTX), DEXCOM INC (DXCM), IMMUNOCORE HLDGS PLC (IMCR), EDGEWISE THERAPEUTICS, INC. (EWTX), BELITE BIO INC (BLTE), WAYSTAR HLDG CORP (WAY), IRONWOOD PHARMACEUTICALS INC (IRWD), KARYOPHARM THERAPEUTICS INC (KPTI), UPSTREAM BIO INC (UPB), GOSSAMER BIO INC (GOSS), INHIBIKASE THERAPEUTICS INC (IKT), IQVIA HLDGS INC (IQV) (IQV), TENET HEALTHCARE CORP (THC), FULCRUM THERAPEUTICS INC (FULC), RAPT THERAPEUTICS INC (RAPT)); reduced holdings in LIQUIDIA CORPORATION (LQDA), APELLIS PHARMACEUTICALS INC (APLS), GLAUKOS CORP (GKOS), ADAGENE INC (ADAG), CYTOMX THERAPEUTICS, INC. (CTMX) — the largest 5 of 23 reductions.
Which positions did Exome Asset Management LLC initiate in Q1 2026?
Exome Asset Management LLC established 14 new positions in Q1 2026: INSMED INC (INSM, 2.6%), MOONLAKE IMMUNOTHERAPEUTICS (MLTX, 2.4%), RHYTHM PHARMACEUTICALS, INC. (RYTM, 2.1%), BOSTON SCIENTIFIC CORP (BSX, 1.8%), ALKERMES PLC (ALKS, 1.7%), MONTE ROSA THERAPEUTICS INC (GLUE, 1.7%), CRESCENT BIOPHARMA INC. (CBIO, 1.7%), RELAY THERAPEUTICS INC (RLAY, 1.6%), MAZE THERAPEUTICS INC (MAZE, 1.6%), AVALO THERAPEUTICS INC (AVTX, 1.4%), SOLENO THERAPEUTICS INC (SLNO, 1.2%), ZENAS BIOPHARMA INC (ZBIO, 0.9%), 4D MOLECULAR THERAPEUTICS IN (FDMT, 0.7%), LIPOCINE INC NEW (LPCN, 0.3%).
Which existing positions saw the largest allocation increases for Exome Asset Management LLC in Q1 2026?
Of 4 existing positions with share-count increases in Q1 2026, the largest were: UNITEDHEALTH GROUP (UNH, +1.1% weight, +120.4% shares), CORBUS PHARMACEUTICALS HLDGS (CRBP, +0.7% weight, +67.8% shares), VERASTEM (VSTM, +0.5% weight, +58.5% shares), NOVABRIDGE BIOSCIENCES (NBP, +-0.1% weight, +15.5% shares).
Which positions did Exome Asset Management LLC fully exit in Q1 2026?
Exome Asset Management LLC fully exited 22 positions in Q1 2026: WAVE LIFE SCIENCES LTD. (WVE, last-reported weight 3.5%), ASTRAZENECA PLC (AZN, last-reported weight 2.6%), JAZZ PHARMACEUTICALS PLC (JAZZ, last-reported weight 2.2%), IMMUNOVANT INC (IMVT, last-reported weight 2.0%), UNIVERSAL HLTH SVCS INC (UHS, last-reported weight 1.9%), DISC MEDICINE INC (IRON, last-reported weight 1.8%), CELCUITY INC (CELC, last-reported weight 1.7%), TRAVERE THERAPEUTICS INC (TVTX, last-reported weight 1.7%), DEXCOM INC (DXCM, last-reported weight 1.6%), IMMUNOCORE HLDGS PLC (IMCR, last-reported weight 1.3%), EDGEWISE THERAPEUTICS, INC. (EWTX, last-reported weight 1.2%), BELITE BIO INC (BLTE, last-reported weight 1.1%), WAYSTAR HLDG CORP (WAY, last-reported weight 1.1%), IRONWOOD PHARMACEUTICALS INC (IRWD, last-reported weight 1.1%), KARYOPHARM THERAPEUTICS INC (KPTI, last-reported weight 1.1%), UPSTREAM BIO INC (UPB, last-reported weight 0.9%), GOSSAMER BIO INC (GOSS, last-reported weight 0.7%), INHIBIKASE THERAPEUTICS INC (IKT, last-reported weight 0.6%), IQVIA HLDGS INC (IQV) (IQV, last-reported weight 0.6%), TENET HEALTHCARE CORP (THC, last-reported weight 0.6%), FULCRUM THERAPEUTICS INC (FULC, last-reported weight 0.5%), RAPT THERAPEUTICS INC (RAPT, last-reported weight 0.2%).
Which existing positions saw the largest allocation reductions for Exome Asset Management LLC in Q1 2026?
Of 23 existing positions with share-count reductions in Q1 2026, the largest were: LIQUIDIA CORPORATION (LQDA, -0.5% weight, -49.8% shares), APELLIS PHARMACEUTICALS INC (APLS, 0.3% weight, -37.0% shares), GLAUKOS CORP (GKOS, -0.4% weight, -33.7% shares), ADAGENE INC (ADAG, 0.7% weight, -30.5% shares), CYTOMX THERAPEUTICS, INC. (CTMX, -0.1% weight, -30.0% shares), NEXTCURE INC (NXTC, -0.4% weight, -30.0% shares), PENUMBRA INC (PEN, -0.2% weight, -30.0% shares), PRAXIS PRECISION MEDICINES I (PRAX, 0.2% weight, -21.8% shares), PALISADE BIO INC (PALI, -0.3% weight, -20.9% shares), CYTOKINETICS INC (CYTK, 0.1% weight, -16.9% shares).
Do quarter-over-quarter 13F allocation changes constitute explicit trading signals?
No. Quarter-over-quarter changes reflect a combination of active trading and market price movement. A weight increase can result from price appreciation alone, without the manager adding shares. Share-count delta is the cleaner indicator of explicit trading activity. All deltas on this page are sourced from sequential SEC Form 13F-HR filings.